Emmanuel Katsanis, MD

Division Chief, Pediatric Hematology / Oncology
Professor, Pediatrics
Louise Thomas Endowed Chair in Pediatric Cancer Research
Program Director, Blood and Bone Marrow Transplant
Professor, Pathology
Professor, Immunobiology
Professor, Medicine
Professor, BIO5 Institute

Dr. Katsanis has more than 27 years of research experience in tumor and transplant immunology. His work has focused on enhancing anti-leukemia activity in hematopoietic cell transplantation (HCT) and chemo-immuno-therapeutic strategies that promote anti-tumor immune responses while overcoming cancer-induced suppression and elucidating the underlying cellular mechanisms involved.

Throughout his career Dr. Katsanis has had strong collaborations, successfully mentored young investigators and have made significant scientific contributions that have moved from bench to bedside. As a physician-scientist, he provides clinical care for children with cancer and blood disorders and conducts research at the Steele Children’s Research Center.

Dr. Katsanis currently serves on NIH grant study sections, numerous international granting organizations and on journal editorial boards. He has published extensively in the areas of cancer immunology and hematopoietic stem cell transplantation. He has received grants from the Medical Research Council of Canada, the National Institutes of Health, the Department of Defense, the Canadian and American Cancer Societies, and the Leukemia and Lymphoma Society.

Degree(s)

  • MD: National University of Athens, Greece, 1980
Internship
McGill University, Montreal, Canada
Residency
University of Ottawa, 1986
Fellowship
University of Ottawa, Pediatric Hematology/Oncology, 1987
University of Minnesota, Pediatric Hematology/Oncology & BMT, 1990
Board Certifications
American Board of Pediatrics
American Board of Pediatrics – Pediatric Hematology-Oncology
Clinical Specialties
Hematology/Oncology
Stem Cell Transplantation
Leukemias and Tumor Immunology
Pediatric Cellular Therapy
Pediatric Medical Oncology
Research Interests

haploidentical hematopoietic cell transplantation (HHCT), graft versus host disease (GvHD), adoptive cell therapies, cancer vaccines, chemo-immunotherapy, immunomodulating agents, experimental HCT models